Lonigutamab  (Synonyms: hz208F2-4)

Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody, serveing as a targeting vector for antibody-drug conjugates (ADCs). Lonigutamab causes G2-M phase cell cycle arrest and increases apoptosis in IGF-1R-overexpressing tumor cells. Lonigutamab demonstrates potent antitumor efficacy in IGF-1R-overexpressing xenograft models. Lonigutamab can be used for the study of Solid tumors with overexpression of IGF-1R and thyroid eye diseases^[1]sup>[2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

IGF1R/CD221

Lonigutamab (0-10 μg/mL, 6 天) 在 IGF-1R 高表达的 MCF-7 (IC₅₀ = 5.1×10^-11 mol/L) 和 NCI-H2122 (IC₅₀ = 6.25×10^-10 mol/L) 细胞中诱导近 100% 的细胞死亡^[1]。
Lonigutamab (10 μg/mL, 10-120 分钟) 在 MCF-7 细胞中显示出快速内化，并与溶酶体共定位^[1]。
Lonigutamab (10 μg/mL, 72 小时) 在 MCF-7 细胞中引起大量的 M 期细胞周期阻滞，并显著增加凋亡和晚期坏死细胞的比例^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Lonigutamab (3 mg/kg, 静脉注射, 每四天一次，共 4 个周期) 显著抑制 MCF-7 乳腺癌、NCI-H2122 肺癌、CaoV3 卵巢癌、Hs746t 和 SBC5 肺癌异种移植模型中的肿瘤生长^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

3480  [NCBI]

P08069

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.12 kDa

2362015-67-4

液体

Colorless to light yellow

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow cytometric analysis of 1X10⁶ MCF-7 cells with Lonigutamab (HY-P99712, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control.

• [1]. Akla B, et al. Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors. Mol Cancer Ther. 2020 Jan;19(1):168-177.  [Content Brief]

  [2]. Pimenta EM, et al. Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity. bioRxiv [Preprint]. 2025 Jan 24:2025.01.20.633920.  [Content Brief]